Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.81 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CBS | P35520 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263014 | 0.89 | EPHX2 (0.65) | EPHX2NPC1RAB9AMITF | |
| SCHEMBL4112779 | 0.89 | EPHX2 (1.00) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4109697 | 0.86 | EPHX2 (0.63) | EPHX2 | |
| SCHEMBL4101592 | 0.86 | EPHX2 (0.79) | EPHX2NPC1RAB9AKMT2A | |
| SCHEMBL30165710 | 0.84 | EPHX2 (0.75) | EPHX2NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1420825 | 0.84 | EPHX2 (0.68) | EPHX2RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4105218 | 0.83 | EPHX2 (0.66) | EPHX2LMNA | |
| SCHEMBL4115733 | 0.82 | EPHX2 (0.70) | EPHX2NPC1RAB9ALMNAKMT2A | |
| SCHEMBL30165709 | 0.80 | EPHX2 (0.76) | EPHX2LMNASMN1; SMN2KMT2A | |
| SCHEMBL4118668 | 0.79 | EPHX2 (0.72) | EPHX2NPC1RAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | EPHX2 503/4885NPC1 625/4885RAB9A 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.